These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26572612)

  • 1. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.
    Portincasa P
    Curr Med Chem; 2016; 23(1):60-86. PubMed ID: 26572612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
    Portincasa P; Scaccianoce G; Palasciano G
    Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.
    Sozeri B; Kasapcopur O
    Curr Med Chem; 2015; 22(16):1986-91. PubMed ID: 25760087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEFV gene compound heterozygous mutations in familial Mediterranean fever phenotype: a retrospective clinical and molecular study.
    Caglayan AO; Demiryilmaz F; Ozyazgan I; Gumus H
    Nephrol Dial Transplant; 2010 Aug; 25(8):2520-3. PubMed ID: 19934083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial Mediterranean fever, review of the literature.
    Alghamdi M
    Clin Rheumatol; 2017 Aug; 36(8):1707-1713. PubMed ID: 28624931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Familial Mediterranean fever – an important disease in a globalised world].
    Wekell P; Karlsson A; Fasth A; Berg S
    Lakartidningen; 2016 Aug; 113():. PubMed ID: 27551868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic approach to familial Mediterranean fever: a review update.
    Ozturk MA; Kanbay M; Kasapoglu B; Onat AM; Guz G; Furst DE; Ben-Chetrit E
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S77-86. PubMed ID: 21968242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial Mediterranean fever in childhood: a single-center experience.
    Barut K; Sahin S; Adrovic A; Sinoplu AB; Yucel G; Pamuk G; Aydın AK; Dasdemir S; Turanlı ET; Buyru N; Kasapcopur O
    Rheumatol Int; 2018 Jan; 38(1):67-74. PubMed ID: 28828621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Familial Mediterranean fever].
    Georgin-Lavialle S; Hentgen V; Stankovic Stojanovic K; Bachmeyer C; Rodrigues F; Savey L; Abbara S; Conan PL; Fraisse T; Delplanque M; Rouet A; Sbeih N; Koné-Paut I; Grateau G
    Rev Med Interne; 2018 Apr; 39(4):240-255. PubMed ID: 29526329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapy in familial Mediterranean fever.
    Koga T; Migita K; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Familial Mediterranean Fever (FMF): from diagnosis to treatment].
    Medlej-Hashim M; Loiselet J; Lefranc G; Mégarbané A
    Sante; 2004; 14(4):261-6. PubMed ID: 15745878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
    Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous necrotizing vasculitis as a manifestation of familial Mediterranean fever.
    Komatsu S; Honma M; Igawa S; Tsuji H; Ishida-Yamamoto A; Migita K; Ida H; Iizuka H
    J Dermatol; 2014 Sep; 41(9):827-9. PubMed ID: 25109905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canakinumab for the treatment of familial Mediterranean fever.
    Ozdogan H; Ugurlu S
    Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.
    Erten S; Erten SF; Altunoglu A
    Rheumatol Int; 2012 Apr; 32(4):1095-7. PubMed ID: 21431291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of familial Mediterranean fever with emphasis on pyrin and colchicine.
    Dbouk HA; Uthman IW
    J Med Liban; 2008; 56(1):35-41. PubMed ID: 19534089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Familial Mediterranean fever: not to be missed].
    Frenkel J; Bemelman FJ; Potter van Loon BJ; Simon A
    Ned Tijdschr Geneeskd; 2013; 157(18):A5784. PubMed ID: 23635502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.
    Ozkan S; Atas B
    J Pak Med Assoc; 2017 Jun; 67(6):945-947. PubMed ID: 28585601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.